GlassScriptPhysician profile
Carson H Rowell
NPI 1285912238
$9,456.62
in general payments reported to CMS, 2019-2025
29 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $585 · 2021: $1,433 · 2022: $1,664 · 2023: $1,402 · 2024: $1,586 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,250.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,227.62 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,626.89 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,445.74 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $864.52 | 2019-2024 | |
| Inari Medical, INC. | $502.30 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $501.20 | 2024-2025 | |
| Gilead Sciences, INC. | $437.16 | 2022-2025 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $427.65 | 2019-2025 | Eliquis |
| Chiesi USA, INC. | $162.95 | 2023-2024 | Cleviprex |
| Boston Scientific Corporation | $151.22 | 2021-2022 | |
| Cvrx, INC. | $130.00 | 2022 | |
| Lilly USA, LLC | $114.10 | 2024 | Zepbound |
| Abbott Laboratories | $108.38 | 2019 | |
| Merck Sharp & Dohme LLC | $94.86 | 2019-2021 | |
| Novo Nordisk INC | $91.11 | 2024 | Ozempic, Rybelsus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $80.89 | 2024 | Pocket Eeg Device |
| Silk Road Medical, INC. | $72.33 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Melinta Therapeutics, LLC | $64.19 | 2022 | |
| Impulse Dynamics (USA) INC. | $61.46 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.39 | 2021-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $44.58 | 2025 | |
| Ferring Pharmaceuticals INC. | $43.18 | 2022-2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $27.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.38 | 2022 | |
| Biomerieux INC | $22.21 | 2023 | |
| Genzyme Corporation | $20.85 | 2020 | |
| Amgen INC. | $18.13 | 2025 | Repatha |
| Galderma Laboratories, L.P. | $17.86 | 2023 | |
| Allergan, INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.